J Reimherr, MD
Psychiatry · Lynn, MANPI 1437178993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,524 of the $77,626 with a category attached, or 67.7%. 28 manufacturers reported payments, led by AbbVie at 29.1% of the total. Reporting peaked in 2019 at $24,043 and has fallen 83.7% since, to $3,911 in 2025. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,141 payments — averaging $68.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Alkermes, Inc.$19K
- Otsuka America Pharmaceutical, Inc.$9K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$6K
- Supernus Pharmaceuticals, Inc.$3K
- Ironshore Pharmaceuticals Inc.$3K
- plus $16K from 22 others
What the payments were for
- Consulting fees$1,2802%
- Speaking & faculty fees$52,52468%
- Travel & lodging$2080%
- Food & beverage$23,40830%
- Education$2060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 199 | $22,624 |
| Alkermes, Inc. | 77 | $18,607 |
| Otsuka America Pharmaceutical, Inc. | 105 | $8,515 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 110 | $5,802 |
| Supernus Pharmaceuticals, Inc. | 42 | $3,491 |
| Ironshore Pharmaceuticals Inc. | 20 | $3,037 |
| Sunovion Pharmaceuticals Inc. | 4 | $2,882 |
| Johnson & Johnson | 91 | $2,326 |
| Lundbeck LLC | 103 | $2,049 |
| Vanda Pharmaceuticals Inc. | 90 | $1,947 |
| Teva Pharmaceuticals USA, Inc. | 75 | $1,808 |
| Neurocrine Biosciences, Inc. | 49 | $1,116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $834 |
| Axsome Therapeutics, Inc. | 46 | $758 |
| Corium, LLC | 19 | $390 |
| E.r. Squibb & Sons, L.L.C. | 17 | $345 |
| Merck | 14 | $224 |
| Shire North American Group Inc | 12 | $206 |
| Indivior Inc. | 8 | $181 |
| Idorsia Pharmaceuticals US Inc | 5 | $105 |
| Vertical Pharmaceuticals, LLC | 5 | $96 |
| Eisai Inc. | 4 | $70 |
| Avanir Pharmaceuticals, Inc. | 3 | $66 |
| Orexo US, Inc. | 4 | $63 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Noven Therapeutics, LLC | 1 | $17 |
| Pear Therapeutics (US), Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$68,883
- VRAYLAR$19,196
- ARISTADA INITIO$17,221
- REXULTI$6,518
- CAPLYTA$3,488
- LATUDA$2,864
- Jornay PM 20mg capsules (Bottle of 100)$2,620
- AUSTEDO$228
- SPRAVATO$114
How this compares
$77,626 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 148 | $211,580 |
| AustedoDeutetrabenazine | 11 | $127,484 |
| AristadaAripiprazole Lauroxil | 20 | $58,153 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 72 | $49,114 |
| FanaptIloperidone | 16 | $44,449 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 280 | $43,391 |
| RexultiBrexpiprazole | 24 | $38,534 |
| CaplytaLumateperone Tosylate | 21 | $37,079 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 61 | $22,836 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 720 | $22,528 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 232 | $20,124 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $17,903 |
| LatudaLurasidone Hcl | 13 | $16,996 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $12,591 |
| Clozapine | 116 | $11,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $22,624 | $211,580148 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,808 | $127,48411 claims |
| Alkermes, Inc.Aristada | $18,607 | $58,15320 claims |
| Indivior Inc.Suboxone | $181 | $49,11472 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,947 | $44,44916 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $8,515 | $38,53424 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $5,802 | $37,07921 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Adderall, Trintellix | $834 | $36,12168 claims |
| Orexo US, Inc.Zubsolv | $63 | $22,83661 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $2,882 | $16,99613 claims |
| Axsome Therapeutics, Inc.Auvelity | $758 | $12,59111 claims |
| MerckBelsomra | $224 | $4,87112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Other psychiatry in Lynn
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Ernesto ZilberbergNorth Andover$141K
- Maurizio FavaBoston$120K
- Craig SurmanCambridge$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.